RCS - Arecor Therapeutics - Arecor Publishes Data for AT278 in Diabetes Care

Arecor TherapeuticsAnnouncement

30/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230130:nRSd2277Oa&default-theme=true

RNS Number : 2277O  Arecor Therapeutics PLC  30 January 2023

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

ARECOR ANNOUNCES PUBLICATION OF PHASE I DATA FOR AT278 IN DIABETES CARE

 

-      Ultra-concentrated, ultra-rapid acting insulin AT278, a promising
candidate in the pursuit of next generation insulins to simplify and improve
glycemic control

 

Cambridge, UK, 30 January 2023: Arecor Therapeutics plc, a globally focused
biopharmaceutical company advancing today's therapies to enable healthier
lives, today announces that the American Diabetes Association journal,
Diabetes Care, has published data from the Company's Phase I clinical trial of
AT278, its ultra-concentrated (500 U/mL), ultra-rapid acting insulin product
candidate.

 

The manuscript, titled 'Pharmacokinetics and Pharmacodynamics of a Novel U500
Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in
People with Type 1 Diabetes', is now available online
(https://doi.org/10.2337/dc22-1054) .

 

In the Phase I clinical study in people with Type I diabetes, AT278 (500 U/mL)
clearly demonstrated faster insulin absorption with an accelerated
pharmacokinetic (PK) and pharmacodynamic (PD) profile compared to
gold-standard insulin NovoRapid® (100 U/mL) despite a 5-fold increase in
concentration.

AT278 is an ultra-concentrated (500 U/mL) novel formulation of insulin that
has been designed to accelerate the absorption of insulin post injection, even
when delivered at a high concentration, and hence via a lower injection
volume. Currently, there are no concentrated (>200 U/mL) rapid acting
insulin products on the market, and therefore, AT278 has the potential to be
the first such product available to patients. It has the potential to enable
more effective management of blood glucose levels to the increasing number of
people with diabetes with high daily insulin requirements (>200 units/day)
whilst maintaining the convenience and compliance benefits of being able to
deliver these high insulin doses in a lower injection volume via a single
injection. In addition, a truly rapid acting concentrated insulin is also a
critical step towards the advancement and miniaturisation of the next
generation of insulin delivery devices.

 

Dr Eva Svehlikova, first author of the study, said: "Publication of these data
in a peer-reviewed journal supports the representation of AT278 as a promising
candidate in the pursuit of next generation insulin analogs designed to
improve postprandial glycemic control with its superior PK/PD profile as well
as reducing the injection volume and/or number of daily injections for people
with diabetes who have high daily insulin needs."

 

Sarah Howell, Chief Executive Officer of Arecor, said:  "Publication of the
AT278 clinical trial in this prestigious journal highlights the significance
of this clinical data and the need for our next generation insulins to bring
improved treatment options to people living with diabetes to simplify and
improve their blood glucose management. As a potential market disrupter, AT278
has the potential to become the gold standard insulin for the growing
population of people with diabetes with high daily insulin needs as well as a
critical enabler in the development of next generation miniaturised insulin
delivery systems. With approximately 537 million people living with diabetes
worldwide, of which approximately 56 million are insulin users, there has
never been a greater need for improved treatment options."

 

AT278 is also currently being investigated in a second Phase I trial in
patients with Type 2 diabetes, to further explore the product's potential to
disrupt the market as the first concentrated, yet rapid acting, insulin. The
study initiated earlier this month and is expected to complete within Q4 2023.

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Susan Lowther, Chief Financial Officer          Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com

 Mo Noonan, Communications                       Tel: +44 (0) 7876 444977

                                                 Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray         Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

 

About Diabetes Care

Diabetes Care is a journal for the health care practitioner that is intended
to increase knowledge, stimulate research, and promote better management of
people with diabetes. For further details please see the website,
https://care.diabetesjournals.org/ (https://care.diabetesjournals.org/)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAWPUQWGUPWUQU